arrow
S

Sophie Leboulleux

department of endocrinology
H指数:83
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer

ENDOCAN TUTHYREF网络共识建议:难治性滤泡性甲状腺癌

2025-05-070
PRE
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

放射性碘难治性不可切除或转移性甲状腺癌的再分化疗法:国际甲状腺肿瘤研究组声明

2025-04-300
OAAI
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
2024-06-271
OAAI
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

凡德他尼在放射性碘治疗无效的局部晚期或转移性分化型甲状腺癌中的应用

2024-06-031
OAAI
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
2023-12-016
OAAI
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

使用来伐替尼治疗放射性碘难治性分化型甲状腺癌: 日常实践的多学科视角

2023-07-101
OAAI
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2023-04-1936
OA